Patents Examined by Melissa S Mercier
  • Patent number: 11964059
    Abstract: A method of delivering a health care active having the steps of administering to a mammal in need of a health benefit or a treatment for a health condition a personal health care article and consuming the article. The article contains one or more filaments that contain a backbone material, a health care active and optionally aesthetic agents, extensional aids, plasticizers, and crosslinking agents.
    Type: Grant
    Filed: January 5, 2021
    Date of Patent: April 23, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Trevor John Darcy, Steven Ray Gilbert, Gregory Charles Gordon, Rajeev Chhabra, William Maxwell Allen
  • Patent number: 11951206
    Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.
    Type: Grant
    Filed: September 29, 2018
    Date of Patent: April 9, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Christopher Thanos, Danya M. Lavin, Briannan E. Bintz, Divya Bhatnagar, John Mills, Megan Billings
  • Patent number: 11944704
    Abstract: The present invention provides a formulation of Coenzyme Q10 that can be re-dispersed from a stable dry powder to formulation to yield a nanodispersion that can be readily aerosolized for inhalation.
    Type: Grant
    Filed: May 3, 2021
    Date of Patent: April 2, 2024
    Assignee: UNM Rainforest Innovations
    Inventors: Jason Thomas McConville, Thiago Cardoso Carvalho, Kristina Schonhoff
  • Patent number: 11938228
    Abstract: A device for delivery of a first therapeutic agent and a second therapeutic agent to a site in epithelial tissue includes a first layer having a first, freeze-dried polymeric matrix having first and second opposed surfaces, formed by a composition including chitosan, a hydration promoter, a particle adhesion inhibitor, and a particle aggregation inhibitor, and a plurality of first particles embedded within the first matrix so as to be directly surrounded by, and in contact with, the first matrix, the first particles containing the first therapeutic agent and having a coating around the first therapeutic agent, the coating including chitosan. The device further includes a second layer, adjacent to the first layer, having a second, freeze-dried polymeric matrix containing the second therapeutic agent, the first layer and/or the second layer is configured to be attached to the site in the epithelial tissue.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: March 26, 2024
    Assignee: PRIVO TECHNOLOGIES, INC.
    Inventors: Manijeh Nazari Goldberg, Brandon LaPorte, Aaron Manzi, Amritpreet Birdi
  • Patent number: 11931485
    Abstract: A biocompatible and bioresorbable implantable device that is intended to be deployed in the middle meningeal artery through intra-arterial catheters and release an anesthetic agent for a prolonged period into the branches of the middle meningeal artery to treat severe headaches including migraine and trigeminal neuralgias. The implantable device may be a mesh with multiple helical loops, fenestrated collapsible hollow shell or spheroid, or folded sheath.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: March 19, 2024
    Inventor: Adnan I. Qureshi
  • Patent number: 11931369
    Abstract: Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.
    Type: Grant
    Filed: July 24, 2023
    Date of Patent: March 19, 2024
    Assignee: POVIVA CORP
    Inventors: John Docherty, Christopher Andrew Bunka
  • Patent number: 11911512
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Grant
    Filed: January 13, 2023
    Date of Patent: February 27, 2024
    Assignee: Purdue Pharma L.P.
    Inventor: Haiyong Hugh Huang
  • Patent number: 11911507
    Abstract: The present invention provides liposomes comprising a lipid bilayer and a polymer-conjugated lipid, wherein said polymer-conjugated lipid is incorporated into said lipid bilayer. The present invention also provides methods of producing the liposomes as well as a method of delivering a nucleic acid to a subject comprising the step of administering said nucleic acid encapsulated in a mixed liposome, a method for performing diagnostic imaging in a subject, comprising the step of administering a diagnostic agent encapsulated in a mixed liposome, and methods for treating, inhibiting, or suppressing a pathological condition in a subject comprising administering to said subject a mixed liposome.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: February 27, 2024
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
    Inventor: Saul Yedgar
  • Patent number: 11911494
    Abstract: Disclosed is a method of treating a fine line or wrinkle in a person's skin, the method comprising topically applying to the fine line or wrinkle a composition comprising an effective amount of Commiphora mukul resin or an extract thereof that includes oleo gum resin, glycerin, water, and hyaluronic acid or a salt form thereof, wherein topical application of the composition to the fine line or wrinkle reduces the appearance of the fine line or wrinkle.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: February 27, 2024
    Assignee: MARY KAY INC.
    Inventors: Tiffany Florence, Michelle Hines, David Gan, Wanli Zhao
  • Patent number: 11903992
    Abstract: The present disclosure provides a composition comprising Lidocaine or salt or hydrate or solvate thereof, L-Carnosine or salt or hydrate or solvate thereof and dexpanthenol or salt or hydrate or solvate thereof. The composition may further comprise one or more other active agents. In an embodiment, the composition is formulated as an oral formulation. The compositions of the present disclosure may find utility in treatment of oral mucositis, ulcers, ulcer mediated pain and the like conditions. Aspects of the present disclosure also relates to method of treating oral, pharyngeal, oropharyngeal and esophageal diseases or conditions using the advantageous compositions of the present disclosure.
    Type: Grant
    Filed: February 10, 2022
    Date of Patent: February 20, 2024
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 11896738
    Abstract: An electrically conductive hyaluronic acid-based hydrogel is disclosed that is a crosslinked porous scaffold having a graphene-based material encapsulated or in contact within the porous scaffold. The graphene-based material includes one or more of graphene oxide foam, reduced graphene oxide foam, nanoplatelets, nanoparticles, or fibers. The porous scaffold may be formed over an implanted bioelectronic device such as a microelectrode array having a plurality of electrodes. The porous scaffold may also be used to control the differentiation of cells including Neural Stem/Progenitor Cells (NS/PCs).
    Type: Grant
    Filed: March 10, 2021
    Date of Patent: February 13, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Rebecca Bierman
  • Patent number: 11896638
    Abstract: A topical skin cream is provided. The topical skin cream includes Acalypha indica oil, Rosa damascena Mill oil, at least one emulsion stabilizer, at least one exfoliant, at least one preservative and water. In an embodiment, the topical skin cream may include Acalypha indica oil, Rosa damascena Mill oil, hydroxypropylmethyl cellulose, polyethylene glycol, sucrose, an alpha-hydroxy acid, water, and at least one preservative. The topical skin cream can be used to treat various related problems, including but not limited to treatment of acne, fungal infections, skin allergies, and other skin conditions.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: February 13, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventor: Nazargi Mahabob
  • Patent number: 11896742
    Abstract: Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: February 13, 2024
    Assignee: COOK MEDICAL TECHNOLOGIES LLC
    Inventors: John Jackson, Lindsay Stuart Machan, Kevin Letchford
  • Patent number: 11891482
    Abstract: The present disclosure relates to the field of polymer chemistry and more particularly to multiblock copolymers comprising a poly(sarcosine) block and a D,L-mixed poly(amino acid) block and uses thereof.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: February 6, 2024
    Assignee: TYNDALL FORMULATION SERVICES, LLC
    Inventors: Kevin N. Sill, Bradford T. Sullivan
  • Patent number: 11883557
    Abstract: A process forms an implantable product including poly(glycerol sebacate) urethane (PGSU) loaded with an active pharmaceutical ingredient (API). The process includes homogeneously mixing a flowable poly(glycerol sebacate) (PGS) resin with the API and a catalyst to form a resin blend. The process also includes homogeneously combining the resin blend with an isocyanate to form a reaction mixture and injecting the reaction mixture to form the PGSU loaded with the API. An implantable product includes a PGSU loaded with an API. In some embodiments, the implantable product includes at least 40% w/w of the API, and the implantable product releases the API by surface degradation of the PGSU at a predetermined release rate for at least three months under physiological conditions. In some embodiments, the PGSU is formed from a PGS reacted with an isocyanate at an isocyanate-to-hydroxyl stoichiometric (crosslinking) ratio in the range of 1:0.25 to 1:1.25.
    Type: Grant
    Filed: May 9, 2022
    Date of Patent: January 30, 2024
    Assignee: THE SECANT GROUP, LLC
    Inventors: Stephanie Reed, Carissa Smoot, Dennis Shull, Todd Crumbling, John D'Ottavio, Peter D. Gabriele, Jeremy J. Harris, Charles Brendan Nicholson, Jared Ely
  • Patent number: 11883536
    Abstract: A method of preparing polylactic acid (PLA) microsphere and polylactic-co-glycolic acid (PLGA) microsphere is provided, including the following steps. A first solution is provided, including polylactic acid or polylactic-co-glycolic acid and an organic solvent. A second solution is provided, including polyvinyl alcohol, sodium carboxymethyl cellulose and an aqueous solution. The first solution is added to the second solution and, at the same time, the second solution is agitated until polylactic acid is solidified to form a plurality of polylactic acid microspheres, or until polylactic-co-glycolic acid is solidified to form a plurality of polylactic-co-glycolic acid microspheres. The polylactic acid microspheres or polylactic-co-glycolic acid microspheres are collected.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 30, 2024
    Assignees: TAIPEI MEDICAL UNIVERSITY, PANION & BF BIOTECH INC.
    Inventors: Ming-Thau Sheu, Yu-Ying Hsu, Yu-De Su, Yu-Hsuan Liu, Pu-Sheng Wei
  • Patent number: 11878079
    Abstract: The instant disclosure provides a capsule composition comprising pullulan, a setting system and a surfactant system that is a sucroglyceride or a sugar fatty acid ester, and methods for making such capsules.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: January 23, 2024
    Assignee: Capsugel Belgium NV
    Inventors: Takahisa Takubo, Claire Geneviève Odile Tardy
  • Patent number: 11878013
    Abstract: The present invention relates to a novel isoquinoline derivative, a preparing method thereof, and a pharmaceutical composition for preventing or treating autophagy related diseases containing the same as an active ingredient. The novel isoquinoline furanone derivative according to the present invention is capable of regulating autophagy activity, and thus, by using this derivative as an active ingredient, there is a useful effect that can be used as a pharmaceutical composition for preventing or treating autophagy-related diseases such as neurodegenerative diseases, cancer, metabolic diseases, inflammatory diseases or melanogenesis-related diseases, a health functional food composition for ameliorating thereof, or a cosmetic composition with a whitening function.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: January 23, 2024
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Myung-Ae Bae, Dae-Seop Shin, Jung Yoon Yang, Kyu Seok Hwang, Seong Soon Kim, Byung Hoi Lee, Ki Young Kim, Won Hoon Jung, Jae Chun Woo
  • Patent number: 11878032
    Abstract: An aqueous saline composition comprising an organic film-protective and/or hyperosmotic compound, the method for obtaining the same, the use thereof as a drug, for example in the form of a spray, for prophylaxis, prevention or adjuvant treatment of ear, nose and throat-(ENT) conditions.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: January 23, 2024
    Inventors: Saïd Djellouli, Andrea Fox
  • Patent number: 11872308
    Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: January 16, 2024
    Assignee: BELHAVEN BIOPHARMA INC.
    Inventors: Scott Lyman, Barry Bleske, Ted William Lanpher